RecruitingNon-Alcoholic Fatty Liver Disease
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
Eligible age
16–20 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
Sponsor: Justin Ryder
You may qualify if…
- ✓ For clinical referral to screening visit:
- ✓ BMI \>30 kg/m2 or \>95th BMI-Percentile
- ✓ Weight Range of 75kg to 150kg
- ✓ Age 16 to \<21 at baseline
- ✓ Elevated alanine aminotransferase (ALT) more than twice the upper limit of normal by gender (≥ 44 U/L for girls, ≥ 50 U/L for boys)63 within 3 months prior to screening (used for historic ALT value) OR diagnosis of NAFLD from ultrasound, MRI, or participants with biopsy-proven NASH within 12 months of screening.
- ✓ History of lifestyle modification to treat obesity or NAFLD.
- ✓ Tanner stage \>2
- ✓ Normal fasting glucose (fasting blood glucose \<100 mg/dL)
You may not qualify if…
- ✕ ALT \> 250U/L at screening
- ✕ History of significant alcohol intake or current use
- ✕ Impaired fasting glucose (\>100 mg/dL)
- ✕ Diabetes (type 1 or 2)
- ✕ Current or recent (\<6 months prior to enrollment) use of weight loss medication(s)
- ✕ Vitamin E supplementation or use of metformin
- ✕ washout period 30 days
- ✕ Previous bariatric surgery
Where it's recruiting
Illinois
Chicago
Source: ClinicalTrials.gov · NCT06355310 · last updated 2026-01-21